8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Feb 26, 2026·SEC
PROCEPT BioRobotics Corporation(PRCT)Earnings, Financials & Key Ratios
PRCT•NASDAQ
$21.03
Price updated Jul 7, 2026
AboutPROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.Show more
- Revenue$308M+37.2%
- EBITDA-$97M-6.7%
- Net Income-$96M-4.5%
- EPS (Diluted)-1.72+1.7%
- Gross Margin63.7%+4.3%
- EBITDA Margin-31.64%+22.3%
- Operating Margin-33.71%+21.7%
- Net Margin-31.02%+23.8%
- ROE-24.89%+7.0%
PRCT Price & Volume
PROCEPT BioRobotics Corporation (PRCT) stock price & volume — 10-year historical chart
Loading chart...
Commercial Scaling Costs Challenge Path Toward Profitability
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Decelerating
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:High commercial scaling costs
Key Thesis Takeaways
- PROCEPT BioRobotics is currently navigating a transition from rapid market penetration to sustainable growth, as evidenced by revenue growth decelerating to 20.2% in 2026Q1.
- While the company has successfully expanded gross margins to 64.9% through a favorable recurring revenue mix, it continues to struggle with operating leverage, evidenced by a $32.6 million operating loss in the most recent quarter.
- Investors should monitor the company's ability to reduce its $65.1 million quarterly SG&A spend, as persistent cash burn and rising stock-based compensation of $13.1 million continue to obscure the path to GAAP break-even.
Verdict Logic
while the company holds a healthy $245.6 million cash balance, the persistent operating loss of $32.6 million and lack of clear operating leverage warrant a cautious wait-and-see approach.
PRCT Growth Metrics
PROCEPT BioRobotics Corporation (PRCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years109.04%
3 Years60.14%
TTM29.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-13.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.06%
Return on Capital
10 Years-38.35%
5 Years-26.44%
3 Years-26.67%
Last Year-22.5%
PRCT Recent Earnings
PROCEPT BioRobotics Corporation (PRCT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.56-1.8%
$0.55
Rev
$83M+3.2%
$81M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.53-65.6%
$0.32
Rev
$76M-18.5%
$94M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.38+7.3%
$0.41
Rev
$83M-11.1%
$94M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.35+14.6%
$0.41
Rev
$79M-6.1%
$84M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.56vs $0.55-1.8% | $83Mvs $81M+3.2% |
| Q1 2026 | Feb 25, 2026 | $0.53vs $0.32-65.6% | $76Mvs $94M-18.5% |
| Q4 2025 | Nov 4, 2025 | $0.38vs $0.41+7.3% | $83Mvs $94M-11.1% |
| Q3 2025 | Aug 6, 2025 | $0.35vs $0.41+14.6% | $79Mvs $84M-6.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for PROCEPT BioRobotics Corporation (PRCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.03 | $1.2B | -12.23 | 37.22% | -31.02% | -24.89% | — | |
| $427.30 | $151.33B | 54.29 | 20.51% | 28.15% | 16.89% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $15.43 | $1.06B | -5.08 | 7.93% | -9.2% | -68.29% | — | |
| $157.03 | $299.63B | 21.84 | 5.97% | 24.14% | 31.42% | — |
Compare PRCT vs Peers
PROCEPT BioRobotics Corporation (PRCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRCT SEC Filings & Documents
PROCEPT BioRobotics Corporation (PRCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PRCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRCT Frequently Asked Questions
PROCEPT BioRobotics Corporation (PRCT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is PROCEPT BioRobotics Corporation's revenue?
PROCEPT BioRobotics Corporation (PRCT) reported $322.0M in revenue for fiscal year 2025. This represents a 5120% increase from $6.2M in 2019.
How fast is PROCEPT BioRobotics Corporation growing?
PROCEPT BioRobotics Corporation (PRCT) grew revenue by 37.2% over the past year. This is strong growth.
Is PRCT profitable?
PROCEPT BioRobotics Corporation (PRCT) reported a net loss of $102.5M for fiscal year 2025.
Dividend & Returns
What is PRCT's return on equity?
PROCEPT BioRobotics Corporation (PRCT) has a return on equity (ROE) of -24.9%. Negative ROE indicates the company is unprofitable.
What is PROCEPT BioRobotics Corporation's free cash flow?
PROCEPT BioRobotics Corporation (PRCT) had negative free cash flow of $80.6M in fiscal year 2025, likely due to heavy capital investments.